Calls
3
Terence Flynn
Editor-in-Chief, Coindesk
Win Rate
33.3%
return
+57.8%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jul 13
$1183.13
-1.8%
Tirzepatide targets both GLP-1 and GIP pathways, delivering better efficacy and tolerability than semaglutide. This differentiation allows branded tirzepatide to command a premium and continue growing even as lower-cost semaglutide generics enter. In ex-US markets, segmentation is already appearing with consumers paying up for tirzepatide, and in the US tirzepatide already holds about 60% market share.
GLP-1 / Obesity
Long
Jul 13
$49.28
-5.1%
Oral GLP-1 options are expanding the US market because the majority of oral users are new to GLP-1s. This market expansion is a strong growth driver, and non-peptide-based orals being easier to scale adds another dimension to monitor, while the existing oral drug is already bringing in fresh demand.
GLP-1 / Obesity
Long
Apr 17
$53.77
+180.3%
GLP-1 therapies are at a convergence moment with five drivers pushing the next phase of adoption: shift to oral medications, expanding access through Medicare, lower costs and broader insurance coverage, global expansion, and innovation beyond weight loss. This could lead to a $190 billion market by 2035 with a bull case of $240 billion, supported by low current penetration and significant growth runway.
Pharma & Biotech
Showing 3 of 3 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Terence Flynn has 3 trade ideas tracked on Buzzberg across 3 tickers since April 2026. Most covered: NVO, LLY, MRNA.
